Share on facebook
Share on google
Share on twitter
Share on linkedin

Cognitive enhancement

  • In 2003 Psychopharmacology published a 60-participant, double-blind study in which subjects who received either a 100 mg or 200 mg of modafinil displayed improved cognitive performance and reported feeling more alert when compared to a placebo group. [Source]
  • In 2013 Neuropharmacology published a double-blind study in which 32 subjects received 200 mg of modafinil and 32 subjects received a placebo. Compared to the placebo group, the modafinil group saw improvements in spatial working memory, planning and decision-making at the most difficult levels. [Source]
  • In 2013 the Public Library of Science published a double-blind, placebo-controlled study which found that a single 100 mg dose of modafinil improved cognitive performance in healthy subjects. MRI brain scans also showed increased activation of the frontal parietal control and dorsal attention networks. [Source]

Decreased fatigue and improved motivation

  • In 2004 Human Psychopharmacology published a double-blind study in which 18 healthy volunteers received either a placebo or an average dose of 300 mg modafinil. Compared to those in the placebo group, subjects who received modafinil experienced improvements in fatigue, motivation, reaction time and vigilance. [Source]

Memory improvement

  • In 2015 Physiology & Behavior published an animal study which found that rats performed maze tests more quickly when receiving modafinil compared to a control group. [Source]

Cocaine dependence

  • In 2010 Drug Alcohol Dependence published a double-blind, 210-patient study which found that 200 mg per day modafinil increased the number of consecutive non-use days in individuals with cocaine addition, when compared to a placebo. [Source]

Fatigue caused by MS

  • In 2010 The Annals of Pharmacotherapy published a meta-analysis of 6 studies which found that in most of studies reviewed modafinil had a positive effect of MS-related fatigue. [Source]
  • In 2010 Clinical Neurology and Neurosurgery published a study which found that modafinil was most beneficial to patients when MS-fatigue was accompanied by daytime sleepiness. [Source]
  •  In 2002 the Journal of Neurology published a 3-month study of in which 47 MS patients were treated with 25-300 mg/day modafinil for 3 months. Eighty-seven percent (41 patients) self-reported clear improvement in fatigue. The authors concluded that low dose modafinil significantly improves fatigue and sleepiness and is well tolerated by MS patients. [Source]

Addition to epileptic drugs

  • In 2015 Psychopharmacology published an animal study which found that modafinil could be a beneficial adjunct to antiepileptic drugs. [Source]

Daytime sleepiness associated with Parkinson’s

  • In 2003 Movement Disorders published a double-blind, crossover study in which 21 Parkinson’s disease patients with sleepiness received either a placebo or 200 mg/day modafinil for 3 weeks. The results showed that modafinil was modestly effective for treating excessive daytime sleepiness associated with Parkinson’s disease. [Source]

Obstructive sleep apnea

  • In 2016 The European Respiratory Journal published a meta-analysis of 10 studies including 1466 patients which found that modafinil and armodafinil improved daytime sleepiness associated with obstructive sleep apnea. [Source]

Severe cancer-related fatigue

  • In 2010 Cancer published a double-blind, placebo-controlled trial of 867 cancer patients undergoing chemotherapy. The results showed that 200 mg/day modafinil was effective in reducing fatigue in patients with severe fatigue but not those with mild or moderate fatigue. [Source]


  • In 2010 Medical Science Monitor published a meta-analysis of 9 trials involving 1,054 patients which showed that modafinil reduced excessive daytime sleepiness as well as the number of sleep attacks and naps per day when compared to a placebo. [Source]

Become a Health Buff!

Get email updates when we publish new content

We will never give away, trade or sell your email address. You can unsubscribe at any time.

Share on facebook
Share on twitter
Share on linkedin
Share on email